Emicizumab-kxwh: First Global Approval

Drugs

Volumn 78, Issue 2, 2018, Pages 269-274

  Scott, Lesley J ^a   Kim, Esther S ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EMICIZUMAB; EMICIZUMAB KXWH; HEMLIBRA; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY;

ABSORPTION HALF-LIFE; ARTHRALGIA; ARTICLE; BLEEDING; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; ELIMINATION HALF-LIFE; ERYTHEMA; FEVER; HEADACHE; HEMATOMA; HEMOPHILIA A; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE REACTION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NECROSIS; SUPERFICIAL THROMBOPHLEBITIS; SWELLING; URTICARIA; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG INTERACTION; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG INTERACTIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85040797644     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-018-0861-2     Document Type: Article

References (18)

1. Adis Insight. Drug profile: emicizumab-kxwh. 2017. http://adis.springer.com/. Accessed 4 Dec 2017.
2. DiMichele DM. Hemophilia therapy: navigating speed bumps on the innovation highway. N Engl J Med. 2016;374(21):2087–9.
3. Lillicrap D. Bispecific antibody therapy in hemophilia. N Engl J Med. 2017;377(9):884–5.
4. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017. https://doi.org/10.1182/blood-2017-08-801662.
5. ® (emicizumab-kxwh) injection: US prescribing information. 2017. http://www.fda.gov. Accessed 4 Dec 2017.
6. US FDA. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors [media release]. http://www.fda.gov. 16 Nov 2017.
7. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348–57.
8. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206–13.
9. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124(20):3165–71.
10. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.
11. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Med. 2012;18(10):1570–4.
12. Adamkewicz J, Schmitt C, Calatzis A, et al. Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 emicizumab (ACE910) phase 3 study [abstract no. OC 47.1]. In: International Society on Thrombosis and Haemostasis Conference. 2017.
13. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–41.
14. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18.
15. Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors [abstract no. 85]. In: ASH 59th Annual Meeting and Exposition. 2017.
16. Young G, Oldenburg J, Liesner R, et al. Efficacy, safety and pharmacokinetics (PK) of once-weekly prophylactic (Px) emicizumab (ACE910) in pediatric (< 12 years) persons with hemophilia A with inhibitors (PwHAwI): interim analysis of single-arm, multicenter, open-label, phase 3 study (HAVEN 2) [abstract no. OC 24.1]. Res Pract Thromb Haemost. 2017;1(Suppl 1):5.
17. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–53.
18. Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891–9.